NCT00409565 2017-10-20
A Phase II Trial of Cetuximab and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer
National Cancer Institute (NCI)
Phase 2 Completed
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center